Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Capital Expenditures (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Capital Expenditures for 6 consecutive years, with $255000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 108.83% to $255000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $969000.0, a 178.45% increase, with the full-year FY2025 number at $969000.0, up 178.45% from a year prior.
  • Capital Expenditures was $255000.0 for Q4 2025 at PROCEPT BioRobotics, up from -$3.9 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $17.4 million in Q4 2023 to a low of -$3.9 million in Q3 2025.
  • A 5-year average of $1.5 million and a median of $236500.0 in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 17470.0% in 2022, then plummeted 1651.83% in 2023.
  • PROCEPT BioRobotics' Capital Expenditures stood at $10000.0 in 2021, then surged by 17470.0% to $1.8 million in 2022, then soared by 888.56% to $17.4 million in 2023, then crashed by 116.62% to -$2.9 million in 2024, then surged by 108.83% to $255000.0 in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Capital Expenditures are $255000.0 (Q4 2025), -$3.9 million (Q3 2025), and $3.2 million (Q2 2025).